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Efforts to reach UNAIDS’ treatment and viral suppression targets have increased demand
for viral load (VL) testing and strained existing laboratory networks, affecting turnaround
time. Longer VL turnaround times delay both initiation of formal adherence counseling and
switches to second-line therapy for persons failing treatment and contribute to poorer health
outcomes.
Methods
We utilized descriptive statistics and logistic regression to analyze VL testing data collected
in Malawi between January 2013 and March 2016. The primary outcomes assessed were
greater-than-median pretest phase turnaround time (days elapsed from specimen collection
to receipt at the laboratory) and greater-than-median test phase turnaround time (days from
receipt to testing).
Results
The median number of days between specimen collection and testing increased 3-fold
between 2013 (8 days, interquartile range (IQR) = 6–16) and 2015 (24, IQR = 13–39)
(p<0.001). Multivariable analysis indicated that the odds of longer pretest phase turn-
around time were significantly higher for specimen collection districts without laboratories
capable of conducting viral load tests (adjusted odds ratio (aOR) = 5.16; 95% confidence
interval (CI) = 5.04–5.27) as well as for Malawi’s Northern and Southern regions. Longer
test phase turnaround time was significantly associated with use of dried blood spots
instead of plasma (aOR = 2.30; 95% CI = 2.23–2.37) and for certain testing months and
testing laboratories.
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Conclusion
Increased turnaround time for VL testing appeared to be driven in part by categorical factors
specific to the phase of turnaround time assessed. Given the implications of longer turn-
around time and the global effort to scale up VL testing, addressing these factors via
increasing efficiencies, improving quality management systems and generally strengthen-
ing the VL spectrum should be considered essential components of controlling the HIV
epidemic.
Introduction
In an effort to control the HIV epidemic and meet the ambitious “90-90-90” targets set forth
by the Joint United Nations Programme on HIV/AIDS (UNAIDS) in 2014 [1], low and middle
income countries (LMICs) have rapidly expanded the number of individuals on antiretroviral
therapy (ART). Globally, the number increased by an estimated 2 million to more than 17 mil-
lion people on ART between the end of 2014 and the end of 2015 [2]. Such regional increases
in ART coverage have intensified the need for scale-up of ART monitoring, for which the cur-
rent gold standard and World Health Organization (WHO) recommendation [3, 4], is viral
load (VL) testing.
Treatment monitoring via VL testing is the standard of care in developed countries and is
preferred over its predecessor, immunological monitoring, because it enables earlier and more
accurate detection of treatment failure [5, 6]. However, a 2012/2013 World Health Organiza-
tion WHO survey of LMICs indicated that just 50% of individuals on ART have access to VL
monitoring [7], and in many countries there are significant barriers to scaling-up VL testing.
Among the most prominent of those barriers are the cost and complexity of VL testing [8],
which limits the number of testing sites and trained technicians in resource-constrained set-
tings [9, 10] and leaves aspects of testing, such as turnaround time, vulnerable [11]. Longer
turnaround time delays initiation of treatment adherence counseling and/or switch to second-
line ART in patients experiencing treatment failure. These delays negate an advantage of
VL testing over immunological monitoring and lead to poorer health outcomes including
increased risk of opportunistic infections [12], prolonged immune activation [13], develop-
ment of drug resistance [14], and increased mortality [15].
Given the links between delayed switch to second-line ART and poor health outcomes,
improved understanding of factors that contribute to longer VL turnaround time, which may
cause such delays, is needed. This is particularly important in the context of viral load scale-up
[16], which may exacerbate the effects of such factors. Thus, this study examined viral load
turnaround time and factors that affected turnaround time using nationally representative VL
testing data from Malawi between 2013 and March 2016, a time period during which there
was rapid scale-up of VL testing.
Methods
Setting
The data utilized in this study were extracted from the Malawi Laboratory Information Man-
agement system (LIMS), established in 2012 and designed to collect laboratory data on all HIV
viral load and early infant diagnosis tests conducted in Malawi. The extraction period for this
analysis was for VL tests conducted from January 1, 2013 to March 31, 2016.
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VL testing in Malawi is initiated at ART clinics, where a VL laboratory requisition form is
completed for each specimen collected. The form includes patient identifiers, demographic
information, the type of specimen collected, and whether the requisition is for a routine or tar-
geted VL test. Following completion of the form, the specimen is transported to one of Mala-
wi’s nine molecular laboratories capable of conducting HIV VL testing. Upon receipt at the
VL testing laboratory, data from the requisition form are entered into the LIMS and the speci-
men is placed in a testing queue. Following testing, the result is entered into the LIMS and a
report is printed for delivery back to the referring clinic and patient. Data from the LIMS at
the nine VL testing labs are routinely synced with a central server via dedicated internet con-
nections. For the period during which data for this study were collected, Malawi’s VL testing
guidelines were in line with WHO treatment recommendations [3, 4].
Measures
Afferent turnaround time was defined as the number of days elapsed between the date of speci-
men collection and the date of specimen testing (Fig 1). More precise measures of turnaround
time within the afferent period were pretest phase turnaround time, which was defined as the
number of days elapsed between specimen collection and receipt at the laboratory; and test
phase turnaround time, which was defined as the number of days elapsed between receipt at
the laboratory and specimen testing. Data on efferent turnaround time was not systematically
collected in Malawi by LIMS or any other means, and thus not included in the analysis. Since
Fig 1. Turnaround time definitions and specimens used in turnaround time calculations. Afferent turnaround time is
defined as the number of days elapsed between specimen collection and specimen testing. Two phases are defined within
afferent turnaround time: Pretest phase, the number of days elapsed between specimen collection and date of receipt at the
laboratory; and Test phase, the number of days elapsed between specimen receipt at the laboratory and the date of testing.
Efferent turnaround time, which was not assessed in this study, is defined as the number of days elapsed between the date of
testing and the date the result is received by the patient. Of 243,539 viral load specimens tested between 2013 and March
2016: 219,121 specimens had valid dates of both specimen collection and testing and thus were included in calculations of
afferent turnaround time, 207,645 specimens had valid dates of both specimen collection and receipt at the laboratory and thus
were included in calculations of pretest phase turnaround time, and 214,786 specimens had valid dates of both receipt and
testing and thus were included in calculations for test phase turnaround time. Valid dates were defined as those that were
present and plausible (e.g., an implausible testing date would be one that fell prior to the specimen collection date).
doi:10.1371/journal.pone.0173009.g001
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Malawi’s LIMS collects data on all specimens undergoing VL testing, regardless of missing or
implausible dates, it was necessary to distinguish between specimens with valid and invalid
dates in order to accurately calculate turnaround time. Valid specimens were defined as those
that had present and plausible collection, receipt, or testing dates depending on the turn-
around time being calculated. All other specimens were excluded from turnaround time calcu-
lations. Overall medians for each phase of turnaround time were calculated and used as cut-
offs to define longer turnaround times. The primary outcomes used in regression analyses
were longer (i.e., greater-than-median) afferent, pretest phase and test phase turnaround time.
Factors included in the analyses were hypothesized a priori to be predictors of longer turn-
around time. Since pretest phase and test phase turnaround times assess different parts of the
VL spectrum, predictors differed by phase. For pretest phase, predictors were: region, presence
of a molecular laboratory in the collection district, and collection month. Region is a geopoliti-
cal distinction defined by the Government of Malawi, presence of a molecular laboratory in
the collection district identifies districts with and without laboratories capable of conducting
viral load testing, and collection month is the month during which the specimen was collected.
Analysis on collection month was conducted using only 2015 data in order to better under-
stand recent temporal trends in turnaround time. Predictors for test phase were: sample type,
testing laboratory, and receipt month. Sample type distinguishes whether the specimen was
collected as a dried blood spot (DBS) or plasma, testing laboratory is a de-identified variable
for the laboratory that conducted the VL test, and receipt month is the month during which
the specimen was received at the testing laboratory. Similar to collection month, analyses on
receipt month were restricted to 2015 data.
Data analyses
Frequencies were generated for categorical variables and means, standard deviations, medians,
and interquartile ranges (IQR) for normally distributed and non-normally distributed contin-
uous variables, respectively. Wilcoxon-Mann-Whitney tests were used to compare specimen
collection volumes and turnaround times.
To examine the relationship between turnaround time and the volume of specimens col-
lected, a variable was created for all valid specimens that was equal to the total number of VL
specimens collected nationally during the same month. That variable was standardized and
assessed for univariate association with longer afferent turnaround time. A similar approach
was utilized to assess the relationship between longer turnaround time and both the volume of
specimens collected per district and the volume of tests conducted per testing laboratory. Uni-
variate and multivariable logistic regression were employed to assess associations between
phase-specific categorical factors and greater-than-median pretest phase and test phase turn-
around times. Factors for both phases were assessed independently and also included in multi-
variable models. Associations with specimen collection and receipt months were restricted to
data collected during 2015, only. All analyses were performed using SAS 9.3 (Cary, NC).
Ethics
The protocol for this analysis was approved by the Centers for Disease Control and Prevention
(CDC) Institutional Review Board (IRB) and the Malawi National Health Science Research
Committee (NHSRC).
Results
Monthly volumes of VL specimens collected increased significantly from 2013 (median: 2,171
tests, IQR = 1,557–3,481) to 2014 (median: 5,622 tests, IQR: 4,276–6,112; p<0.001) and from
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2014 to 2015 (median: 10,296, IQR: 9,001–12,025; p = 0.002). This was paralleled by year-to-
year increases in the number of clinics referring specimens for viral load testing and median
afferent turnaround time. Overall, the vast majority (97.6%) of VL tests were conducted on
specimens referred for routine testing, which had a higher median turnaround time (median:
21 days, IQR: 10–41) compared to specimens referred for targeted testing (median: 10 days,
IQR: 6–19). Most specimens (86.1%) had a VL result that was less than or equal to 1000 cop-
ies/ml (Table 1).
Nationally, while greater volumes of viral load specimens collected per month were associ-
ated with longer afferent turnaround time (odds ratio (OR) = 2.65, 95% confidence interval
(CI) = 2.64–2.68), greater volumes of specimens collected per district (OR = 0.45, 95% CI =
0.45–0.46) and greater volumes of specimens tested per laboratory (OR = 0.65, 95% CI = 0.65–
0.66) were not. Fig 2 graphically shows more precise breakdowns of this relationship. In Fig
2A, median pretest phase turnaround times track monthly changes in national specimen col-
lection volumes, but that is not the case for district specimen collection volumes arranged in
ascending order (Fig 2B). Similarly, median test phase turnaround time trends alongside
monthly changes in the national volume of specimens received (Fig 2C), but no such relation-
ship is evident between test phase turnaround time and the volume of specimens received at
laboratories (Fig 2D).
Categorical predictors of longer pretest phase turnaround time were assessed (Table 2). In
univariate models, the odds of longer turnaround time were slightly increased for Malawi’s
Northern and Southern regions compared to the Central region and substantially increased
for districts without molecular laboratories compared to those with molecular laboratories.
For 2015 specimen collection month, only February had significantly decreased odds of longer
turnaround time compared to the reference month of January.
Adjusting for multiple predictors in the same model affected associations between longer
pretest phase turnaround time and categorical factors. Compared to the univariate model, the
odds of longer turnaround time for Malawi’s Northern and Southern regions increased in the





















2013 32,516 124 3 8 (6–16) 1,847, 5.7% 29,199, 93.2% 27,954, 86.0%
2014 61,579 268 6 14 (7–25) 25,325, 41.1% 58,844, 97.1% 52,061, 84.5%






45,596 571 9 48 (34–67) 39,523, 86.7% 45,159, 99.5% 40,650, 89.2%
2013-Mar
2016
243,539 - - 21 (10–41) 141,425, 58.1% 234,020,
97.6%
209,690, 86.1%
Values are reported as median (interquartile range) or n, %.
Specimens tested: all viral load specimens tested and recorded in the LIMS. Clinics referring specimens for viral load testing: the number of clinics in the
given year that referred1 specimen for viral load testing. Laboratories conducting viral load testing: the number of laboratories in the given year that
conducted1 viral load test. Median afferent TAT: median number of days from specimen collection date to specimen testing date, values calculated using
only specimens with valid dates. DBS specimens: specimens collected as dried blood spots (vs. plasma). Routine tests: viral load specimens collected for
routine (vs. targeted) testing. Virally suppressed: viral load result 1000 copies/ml.
Abbreviations: TAT, afferent turnaround time; IQR, Interquartile range; DBS, dried blood spot.
a Values increased significantly from 2013 to 2014 (p<0.001), from 2014 to 2015 (p<0.001), and from 2015 to 2016 (p<0.001) Wilcoxon-Mann-Whitney test.
doi:10.1371/journal.pone.0173009.t001
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Fig 2. Volumes of viral load specimens collected/received/tested and corresponding median pretest phase and
test phase turnaround times. 2(A) National number of specimens collected and referred for viral load testing by month
and corresponding monthly median pretest phase turnaround time. 2(B) Number of specimens referred by district and
corresponding median pretest phase turnaround time by district. 2(C) National number of specimens received at the
laboratory for viral load testing by month and corresponding monthly median test phase turnaround time. 2(D) Number of
specimens received per laboratory and corresponding median test phase turnaround time by laboratory. All pretest and
test phase turnaround times were calculated using only specimens with valid dates.
doi:10.1371/journal.pone.0173009.g002
Table 2. Factors associated with longer pretest phase turnaround time for viral load specimens collected in Malawi, 2013-March 2016.
Factor Specimens
collecteda




Adjusted ORb (95% CI)




Central 85,840 6 (0–14) ref ref




Molecular Lab in Collection
District




Yes 142,317 2 (0–8) ref ref
2015 Collection Month January 5,144 7 (1–13) ref ref












































Logistic regression was utilized to model the relationship between longer pretest phase turnaround time and “Region”, “Molecular Lab in Collection District”,
and “2015 Collection Month”. Referent categories were ‘Central Region’, districts with molecular labs (i.e., ‘Yes’), and ‘January’, respectively. In the adjusted
models, the relationship between longer pretest phase turnaround time and a given factor was adjusted for the other two factors presented in the table (e.g.,
the adjusted model for region was adjusted for “Molecular Lab in Collection District” and “Specimen Collection Month”). ‘Specimen Collection Month’ as a
factor in the adjusted model included both the month and year (e.g., September 2014). Longer pretest phase turnaround time was defined as greater-than-
median pretest phase turnaround time.
Abbreviations: TAT, turnaround time; IQR, Interquartile range; OR, odds ratio; CI, confidence interval.
a Specimens collected reflects the total number of specimens collected, regardless of validity. Note that specimens collected per 2015 collection month
includes only specimens collected during 2015.
b Specimens included in the turnaround time calculation and regression analyses for “Region” and “Molecular Lab in Collection District” (n = 207,638).
Specimens included in the turnaround time calculation and regression analyses for “2015 Collection Month” (n = 112,524).
doi:10.1371/journal.pone.0173009.t002
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adjusted model, while the odds of longer turnaround time for districts without molecular labo-
ratories decreased slightly upon adjustment (Table 2). In the adjusted model for collection
month, the odds of longer turnaround time were decreased for some months, but increased
for others relative to the univariate model; reflecting inter-month variability in factors’ influ-
ence on turnaround time.
Categorical predictors of longer test phase turnaround time were also assessed (Table 3).
The univariate odds of longer turnaround time for DBS were increased compared to plasma.
For testing laboratories and 2015 receipt month, some laboratories and months had increased




Median test phase TATb (IQR),
days
Unadjusted ORb (95% CI) Adjusted ORb (95% CI)
Sample Type DBS 141,425 18 (8–30) 3.32 (3.26–3.39), p<0.001 2.30 (2.23–2.37), p<0.001
Plasma 101,914 7 (3–18) ref ref
Testing Lab A 20,370 4 (1–7) 0.30 (0.29–0.32), p<0.001 0.40 (0.37–0.42), p<0.001
B 7,308 30 (15–50) 5.41 (5.02–5.82), p<0.001 4.03 (3.69–4.39), p<0.001
C 37,594 11 (4–34) 1.36 (1.32–1.40), p<0.001 2.80 (2.70–2.91), p<0.001
D 14,594 14 (8–24) 1.61 (1.55–1.68), p<0.001 1.27 (1.21–1.33), p<0.001
E 24,847 16 (7–25) 1.98 (1.91–2.05), p<0.001 2.15 (2.06–2.24), p<0.001
F 39,084 11 (5–20) ref ref
G 29,258 21 (12–31) 3.61 (3.49–3.72), p<0.001 3.72 (3.57–3.87), p<0.001
H 48,754 8 (5–17) 0.74 (0.72–0.76), p<0.001 0.57 (0.55–0.60), p<0.001
I 21,730 20 (10–37) 3.37 (3.26–3.49), p<0.001 2.71 (2.60–2.82), p<0.001
2015 Receipt
Month
January 5,049 8 (3–21) ref ref
February 7,100 6 (4–13) 0.47 (0.43–0.51), p<0.001 0.31 (0.28–0.34), p<0.001
March 8,362 9 (4–18) 0.87 (0.81–0.94), p<0.001 0.58 (0.54–0.63), p<0.001
April 8,871 7 (5–13) 0.41 (0.37–0.44), p<0.001 0.23 (0.21–0.25), p<0.001
May 8,132 10 (5–23) 1.15 (1.06–1.24), p<0.001 0.73 (0.67–0.80), p<0.001
June 10,850 7 (3–25) 0.97 (0.90–1.04), p = 0.36 0.75 (0.69–0.81), p<0.001
July 10,549 21 (13–27) 4.64 (4.31–4.99), p<0.001 3.39 (3.12–3.67), p<0.001
August 12,095 12 (6–18) 1.17 (1.09–1.26), p<0.001 0.77 (0.71–0.83), p<0.001
September 10,857 16 (9–30) 1.91 (1.78–2.06), p<0.001 1.35 (1.24–1.46), p<0.001
October 12,566 31 (14–42) 4.95 (4.60–5.32), p<0.001 3.83 (3.54–4.16), p<0.001




December 11,427 29 (20–47) 10.01 (9.24–10.85),
p<0.001
6.22 (5.69–6.80), p<0.001
Logistic regression was utilized to model the relationship between longer test phase turnaround time and “Sample Type”, “Testing Lab”, and “2015 Receipt
Month”. Referent categories were ‘Plasma’, ‘Laboratory F’, and ‘January’, respectively. Laboratory F served as the referent category because it had the
highest number of specimens included in the analysis. In the adjusted models, the relationship between longer test phase turnaround time and a given
factor was adjusted for the other two factors presented in the table (e.g., the adjusted model for “Sample Type” was adjusted for “Testing Lab” and
“Specimen Receipt Month”). ‘Specimen Receipt Month’ as a factor in the adjusted model included both the month and year (e.g., September 2014). Longer
test phase turnaround time was defined as greater-than-median test phase turnaround time.
Abbreviations: TAT, turnaround time; IQR, Interquartile range; OR, odds ratio; CI, confidence interval.
a Specimens received reflects the total number of specimens received, regardless of validity. Note that the number of specimens received per 2015 receipt
month includes only specimens received during 2015.
b Specimens included in the turnaround time calculation and regression analyses for “Sample Type” and “Testing Lab” (n = 214,601). Specimens included in
the turnaround time calculation and the regression analyses for “2015 Receipt Month” (n = 107,479).
doi:10.1371/journal.pone.0173009.t003
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univariate odds of longer turnaround time while others had decreased odds compared to their
respective reference categories. The months of July, October, November and December stood
out with particularly high odds of longer test phase turnaround time.
In an adjusted model, the odds of longer turnaround time for DBS were decreased relative
to the univariate model, though still significantly higher than for plasma. For testing labora-
tory, Table 3 shows that after adjustment, the odds of longer turnaround time increased for
some laboratories, but decreased for others.
Discussion
This study shows that increased turnaround time for VL testing appeared to be driven in part
by categorical factors specific to the phase of turnaround time assessed. Indeed, factors, such
as the presence of a molecular testing laboratory in the collection district, specimen type, and
testing laboratory appeared to contribute to longer turnaround time; potentially putting
patients at risk of poorer health outcomes by delaying adherence counseling and/or switch to
second-line therapy. Shortening afferent turnaround time and ensuring that health outcomes
are not affected by laboratory or operational delays will require identification of the specific
causes responsible for longer turnaround time and implementation of measures to mitigate
those causes in the future.
While turnaround times were lower in districts and laboratories that collected and received
higher volumes of specimens (Fig 2B and 2D), suggesting factors such as familiarity with work-
flow shorten turnaround time, a similar relationship between increasing specimen volumes
and shortened turnaround time was not evident on a national scale (Fig 2A and 2C). These
data, along with the overall increase in median afferent turnaround time between 2013 and
2015, support the assertion that factors contributing to shorter turnaround time, were out-
weighed by factors contributing to longer turnaround time. Understanding what those factors
are, how they influence turnaround time, and in which ways they can be addressed is an
important step in the effort to shorten turnaround time.
HIV VL testing’s dependence on expensive equipment, dedicated laboratory space and
highly trained technicians limits its accessibility for many ART patients in LMICs [9, 10]. The
current preferred strategy to overcome this accessibility problem is through centralized testing
and a robust sample transport network. Use of DBS instead of plasma, which in many cases
requires neither a phlebotomist nor a cold-chain, further enhances the cost-effectiveness and
feasibility of centralized testing. WHO recommends that DBS can be used effectively at a
threshold of 1000 copies/ml in most laboratory settings [17], and its feasibility has been docu-
mented as part of a centralized testing network in Malawi [18]. However, impacts of central-
ized testing and use of DBS on aspects of the VL spectrum such as turnaround time have been
largely overlooked in published studies.
Of Malawi’s 28 districts, just seven have molecular laboratories capable of conducting viral
load testing. The remaining 21 districts refer specimens to those districts with molecular test-
ing laboratories. Our results indicated that districts without a molecular laboratory were asso-
ciated with longer pretest phase turnaround time, suggesting that efficiency of specimen
transfer to centralized testing sites may be one factor driving longer turnaround time in
Malawi. In particular, the association with longer pretest phase turnaround time points to
specimen transport time and/or time spent waiting for transport as possible drivers of the
association.
We also found that use of DBS for VL testing has significantly higher odds of longer test
phase turnaround time compared to plasma. While DBS typically travels further than plasma
on its way to testing labs in Malawi, the association with test phase turnaround time, which
HIV viral load testing turnaround times
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measures time elapsed between receipt at the laboratory and testing, links DBS to more time
spent in the laboratory. This association suggests that there are factors that delay testing of
DBS specimens. Those factors may include technicians untrained in DBS preparation, bottle-
necks related the DBS sorting and specimen rejection process, or preference for plasma due to
pressure from nearby clinics, ease of preparation or limited cold-storage.
While centralization of testing and use of DBS increases access to VL monitoring, it is nev-
ertheless susceptible to inconsistent specimen transport networks, staff shortages, weather,
holidays, reagent stock-outs, equipment problems and administrative delays. Several of these
factors have been noted as barriers to VL scale-up [19, 20] and many have also been docu-
mented in perception and feasibility studies [11, 21]. Whether or not these factors affect VL
testing and thus turnaround time is largely dependent on where and when the specimen was
collected and where and when the testing occurred.
Our data indicated that certain testing labs had much stronger associations with longer test
phase turnaround time than others, suggesting that factors such as those mentioned previously
play a role in laboratory to laboratory variation. Factors related to staffing, supplies or adminis-
tration may be responsible for the differences between labs, but it is difficult to know without
intimate knowledge of the lab. Our models also indicated that certain specimen collection
months had higher odds of longer pretest phase turnaround time and certain receipt months
had higher odds of longer test phase turnaround time. The collection months of April, May,
November and December of 2015, for example, stood out with increased odds of longer pretest
phase turnaround time, suggesting that issues related to sample transport such as poor weather
or a fuel shortages may have been present during those months. Similarly, specimens received
during November and December 2015 had substantially higher odds of longer test phase turn-
around time, which may be linked may to reagent stock-outs or staff leave due to holidays.
While our results do not pinpoint the exact causes of longer turnaround time, they reveal
the scope of the problem, inform strategies for improvement, and provide baseline data to
assess future improvement efforts. Perhaps the clearest strategies to shorten turnaround time
are to increase efficiencies and improve quality management systems (QMS) across the VL
spectrum. Implementing these strategies in LMICs, however, is challenging, particularly
implementation of comprehensive QMS. Thus, use of focused, data-driven investigations into
laboratory quality issues in lieu of comprehensive QMS may be a more feasible option. The
key to such investigations are data collection systems reminiscent of Malawi’s LIMS, which are
akin to surveillance systems long utilized in public health to detect and respond to disease out-
breaks. In the case of LIMS, though, the disease is sub-standard laboratory quality, such as
long turnaround time, and the response is a targeted investigation to identify and address
causes responsible for that sub-standard quality. Future efforts in Malawi and elsewhere should
treat such systems, many of which are already in existence, as they would traditional surveil-
lance systems; that is, the data being collected should be regularly monitored and the system
collecting the data should be periodically evaluated. Optimized use of these systems will enable
LMICs to efficiently utilize resources to improve laboratory quality and ensure that health out-
comes are not compromised.
The implications of shortened turnaround time are not limited to improved health out-
comes. Other aspects of the VL spectrum, such as demand for and quality of VL testing are
essential to reaching the 90-90-90 goals [1] and may also be positively affected by shortened
turnaround time. A 1989 study conducted in an American hospital alluded to a phenomenon
in which the number and type of tests ordered within the hospital were influenced by turn-
around time, and suggested that decentralization of testing could shorten turnaround time
[22]. While the setting is vastly different, that study is echoed by recent anecdotal reports from
Malawi that suggest demand for VL testing and movement toward decentralized testing are
HIV viral load testing turnaround times
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influenced by turnaround time. Specifically, longer turnaround times may be decreasing
demand for VL testing and driving decentralization via adoption of point-of-care (POC) tech-
nology, which, though promising, raises concerns about quality [23, 24]. These and other turn-
around time-affected aspects lend additional urgency to turnaround time improvement
efforts.
Key strengths of this study include the nationally-representative data and the focus on fac-
tors that affect turnaround time for VL testing not only in Malawi, but in many LMICs. These
data contribute to a better understanding of VL turnaround time and provide evidence that
supports the need for a stronger, more efficient VL spectrum. Limitations include the access to
data only for afferent turnaround time, which limits our ability to connect findings to patient
indicators such as adherence counseling, treatment switches, and patient notification of VL
results. Additionally, an adequate duration for HIV VL testing turnaround time has not been
identified by either the Malawi Ministry of Health or international health bodies such as the
WHO. This lack of a proverbial ‘measuring stick’ for turnaround time limits our ability to
judge the adequacy of the turnaround times observed in Malawi. Finally, there were a substan-
tial number of VL specimens with missing and/or implausible date combinations, which were
omitted from turnaround time calculations.
Conclusions
Longer afferent turnaround times for VL testing were observed in Malawi and appeared to be
driven in a phase-specific manner by factors such as the presence of a molecular lab in the col-
lection district, the type of specimen collected, the month that the specimen was collected, and
the laboratory where the test was run. Given turnaround time’s impact on the VL spectrum,
addressing the specific causes of longer turnaround time nested within these factors is critically
important. Strengthening the VL spectrum via increasing efficiencies, improved QMS, and
capacity to conduct data-driven investigations into laboratory quality issues are initiatives
that should be considered essential to reaching the 90-90-90 targets and controlling the HIV
epidemic.
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